Aurobindo Pharma USA, Inc. entered into a definitive agreement to acquire Lannett Company, Inc. in a transaction valued at $250 million on July 30, 2025. A cash consideration will be paid by Aurobindo Pharma USA, Inc. Enterprise value of $250 million on a cash free debt free basis and including normalized levels of working capital.

For the period ending December 31, 2024, Lannett Company, Inc. reported total revenue of $286 million.

The transaction shall be subject to US Federal Trade Commission approval and any other statutory and government approvals as may be necessary. The expected completion of the transaction is in eight to ten months. The necessary approval from US Federal Trade Commission (FTC) for the acquisition of the Lannett business has been obtained. The FTC is requiring Aurobindo Pharma Limited to divest four different generic drug products to complete its $250 million acquisition of Lannett Company Inc. The transaction is expected to close before the end of June 2026. The transaction is expected to be immediately accretive to Aurobindo Group?s earnings per share.

Sullivan & Cromwell LLP acted as legal advisor for Aurobindo Pharma USA, Inc. Ice Miller LLP acted as legal advisor for Aurobindo Pharma USA, Inc. Khaitan & Co. acted as legal advisor for Aurobindo Pharma USA, Inc. Ernst & Young Private Limited acted as financial advisor for Aurobindo Pharma USA, Inc. KNAV acted as accountant for Aurobindo Pharma USA, Inc. Raymond James & Associates, Inc. acted as financial advisor for Lannett Company, Inc. Honigman LLP acted as legal advisor for Lannett Company, Inc. Dechert LLP acted as legal advisor for Lannett Company, Inc.